Ascelia Pharma AB (publ)

Stockholm Stock Exchange ACE.ST

Ascelia Pharma AB (publ) Price to Earnings Ratio (P/E) on January 14, 2025: -2.25

Ascelia Pharma AB (publ) Price to Earnings Ratio (P/E) is -2.25 on January 14, 2025, a 37.78% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Ascelia Pharma AB (publ) 52-week high Price to Earnings Ratio (P/E) is -1.62 on November 06, 2024, which is 27.80% above the current Price to Earnings Ratio (P/E).
Ascelia Pharma AB (publ) 52-week low Price to Earnings Ratio (P/E) is -7.40 on April 17, 2024, which is -229.50% below the current Price to Earnings Ratio (P/E).
Ascelia Pharma AB (publ) average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.60.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Stockholm Stock Exchange: ACE.ST

Ascelia Pharma AB (publ)

CEO	Mr. Magnus O. Corfitzen
IPO Date	March 13, 2019
Location	Sweden
Headquarters	Hyllie Boulevard 34
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.

Key trends

Past 5 years